In a phase Ib trial, a combination of the experimental immunotherapy AM0010, a PEGylated form of the recombinant human cytokine IL10, and the anti–PD-1 checkpoint inhibitor pembrolizumab was well tolerated and effective at controlling tumors in some patients with advanced renal cell carcinoma, non–small cell lung cancer, and melanoma.
http://ift.tt/2gWXIjl
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου